Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Survodutide

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Boehringer Ingelheim · Phase 1 · Completed · Enrollment 88

NCT05751226

EudraCT 2022-002733-34

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
BI 1820237 treatment groupn/rn/rn/rn/r
Placebo groupn/rn/rn/rn/r
BI 1820237 + semaglutide treatment groupn/rn/rn/rn/r
placebo + semaglutide groupn/rn/rn/rn/r
BI 1820237 + BI 456906 treatment groupn/rn/rn/rn/r
placebo + BI 456906 groupn/rn/rn/rn/r

Not shown

  • BI 1820237 treatment group: endpoint not reported
  • Placebo group: endpoint not reported
  • BI 1820237 + semaglutide treatment group: endpoint not reported
  • placebo + semaglutide group: endpoint not reported
  • BI 1820237 + BI 456906 treatment group: endpoint not reported
  • placebo + BI 456906 group: endpoint not reported